{"id":58550,"date":"2026-03-02T14:00:50","date_gmt":"2026-03-02T06:00:50","guid":{"rendered":"https:\/\/flcube.com\/?p=58550"},"modified":"2026-03-02T14:00:51","modified_gmt":"2026-03-02T06:00:51","slug":"innocares-zurletrectinib-wins-priority-review-for-pediatric-ntrk-tumors-next-gen-trk-inhibitor-expands-label","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58550","title":{"rendered":"InnoCare&#8217;s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label"},"content":{"rendered":"\n<p><strong>InnoCare Pharma Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA:\u202f688428<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG:\u202f9969<\/a>)<\/strong> announced that the <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>Priority Review<\/strong> to <strong>zurletrectinib (ICP\u2011723) orally disintegrating tablets<\/strong> for the treatment of <strong>pediatric patients (ages 2\u201312)<\/strong> with <strong>solid tumors harboring NTRK gene fusions<\/strong>. The designation follows the <strong>December\u202f2025 approval<\/strong> for adult and adolescent patients (\u2265\u202f12 years), expanding the <strong>next\u2011generation TRK inhibitor&#8217;s<\/strong> addressable population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Zurletrectinib (ICP\u2011723) \u2013 orally disintegrating tablets<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Next\u2011generation TRK inhibitor<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>Independently developed in China<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>CDE Priority Review granted<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Pediatric patients (2\u201312 years) with NTRK fusion\u2011positive solid tumors<\/td><\/tr><tr><td><strong>Prior Approval<\/strong><\/td><td>Dec\u202f2025: Adults and adolescents (\u2265\u202f12 years) with NTRK fusion\u2011positive solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-differentiation-next-generation-trk-inhibitor\">Clinical Differentiation \u2013 Next\u2011Generation TRK Inhibitor<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Zurletrectinib Advantage<\/th><th>Clinical Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Superior Efficacy<\/strong><\/td><td>vs. first\u2011generation TRK inhibitors<\/td><td>Enhanced tumor response rates<\/td><\/tr><tr><td><strong>Long\u2011Term Deep Remission<\/strong><\/td><td>Sustained clinical benefit<\/td><td>Durable disease control<\/td><\/tr><tr><td><strong>High Brain Permeability<\/strong><\/td><td>CNS penetration<\/td><td>Efficacy in brain metastases and primary CNS tumors<\/td><\/tr><tr><td><strong>Favorable Safety<\/strong><\/td><td>Manageable toxicity profile<\/td><td>Improved tolerability vs. competitors<\/td><\/tr><tr><td><strong>Resistance Overcome<\/strong><\/td><td>Active against first\u2011gen resistance mutations<\/td><td>Treatment option for relapsed patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric Oncology Focus:<\/strong> The <strong>2\u201312 year age expansion<\/strong> addresses a <strong>vulnerable population<\/strong> with limited treatment options; Priority Review reflects NMPA&#8217;s commitment to <strong>pediatric rare disease<\/strong> acceleration.<\/li>\n\n\n\n<li><strong>NTRK Tumor\u2011Agnostic Strategy:<\/strong> NTRK fusions occur across <strong>diverse pediatric solid tumors<\/strong> (infantile fibrosarcoma, congenital mesoblastic nephroma, secretory breast cancer); zurletrectinib&#8217;s <strong>tumor\u2011agnostic mechanism<\/strong> enables broad applicability.<\/li>\n\n\n\n<li><strong>Brain Penetration Differentiation:<\/strong> <strong>High CNS activity<\/strong> distinguishes zurletrectinib from competitors, addressing <strong>brain metastases<\/strong>\u2014a common site of progression in NTRK\u2011positive malignancies.<\/li>\n\n\n\n<li><strong>Resistance Mechanism Solution:<\/strong> Capability to <strong>overcome first\u2011generation TRK inhibitor resistance<\/strong> positions zurletrectinib as <strong>salvage therapy<\/strong> and potentially <strong>front\u2011line option<\/strong> to prevent resistance emergence.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>NTRK Fusion Prevalence<\/strong><\/td><td>~\u202f0.3% of solid tumors; higher in pediatric populations (1\u20112% of certain sarcomas, infantile cancers)<\/td><\/tr><tr><td><strong>First\u2011Gen TRK Inhibitors<\/strong><\/td><td>Larotrectinib (Bayer\/Loxo) and entrectinib (Roche) approved but resistance emerges in 12\u201124 months; CNS penetration limitations<\/td><\/tr><tr><td><strong>Pediatric Priority Review<\/strong><\/td><td>Accelerated 130\u2011day review timeline; supports rapid access for life\u2011threatening rare pediatric cancers<\/td><\/tr><tr><td><strong>InnoCare Pipeline Validation<\/strong><\/td><td>Second NMPA approval\/priority review demonstrates platform consistency; supports global partnership potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding pediatric approval timelines, label expansion, and commercial potential for zurletrectinib. Actual results may differ due to risks including competitive first\u2011gen TRK inhibitor entrenchement, pediatric trial enrollment challenges, and long\u2011term resistance monitoring.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969) announced that the Center for Drug Evaluation (CDE) of China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,919,327,68,80],"class_list":["post-58550","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-9969","tag-innocare-pharma","tag-pediatric-drugs","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare&#039;s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969) announced that the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) has granted Priority Review to zurletrectinib (ICP\u2011723) orally disintegrating tablets for the treatment of pediatric patients (ages 2\u201312) with solid tumors harboring NTRK gene fusions. The designation follows the December\u202f2025 approval for adult and adolescent patients (\u2265\u202f12 years), expanding the next\u2011generation TRK inhibitor&#039;s addressable population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58550\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare&#039;s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969) announced that the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) has granted Priority Review to zurletrectinib (ICP\u2011723) orally disintegrating tablets for the treatment of pediatric patients (ages 2\u201312) with solid tumors harboring NTRK gene fusions. The designation follows the December\u202f2025 approval for adult and adolescent patients (\u2265\u202f12 years), expanding the next\u2011generation TRK inhibitor&#039;s addressable population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58550\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T06:00:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T06:00:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0207.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare&#8217;s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label\",\"datePublished\":\"2026-03-02T06:00:50+00:00\",\"dateModified\":\"2026-03-02T06:00:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550\"},\"wordCount\":426,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0207.webp\",\"keywords\":[\"Cancer\",\"HKG: 9969\",\"InnoCare Pharma\",\"Pediatric drugs\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58550#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58550\",\"name\":\"InnoCare's Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0207.webp\",\"datePublished\":\"2026-03-02T06:00:50+00:00\",\"dateModified\":\"2026-03-02T06:00:51+00:00\",\"description\":\"InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Priority Review to zurletrectinib (ICP\u2011723) orally disintegrating tablets for the treatment of pediatric patients (ages 2\u201312) with solid tumors harboring NTRK gene fusions. The designation follows the December\u202f2025 approval for adult and adolescent patients (\u2265\u202f12 years), expanding the next\u2011generation TRK inhibitor's addressable population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58550\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0207.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0207.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare's Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58550#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare&#8217;s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare's Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Priority Review to zurletrectinib (ICP\u2011723) orally disintegrating tablets for the treatment of pediatric patients (ages 2\u201312) with solid tumors harboring NTRK gene fusions. The designation follows the December\u202f2025 approval for adult and adolescent patients (\u2265\u202f12 years), expanding the next\u2011generation TRK inhibitor's addressable population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58550","og_locale":"en_US","og_type":"article","og_title":"InnoCare's Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label","og_description":"InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Priority Review to zurletrectinib (ICP\u2011723) orally disintegrating tablets for the treatment of pediatric patients (ages 2\u201312) with solid tumors harboring NTRK gene fusions. The designation follows the December\u202f2025 approval for adult and adolescent patients (\u2265\u202f12 years), expanding the next\u2011generation TRK inhibitor's addressable population.","og_url":"https:\/\/flcube.com\/?p=58550","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T06:00:50+00:00","article_modified_time":"2026-03-02T06:00:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0207.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58550#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58550"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare&#8217;s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label","datePublished":"2026-03-02T06:00:50+00:00","dateModified":"2026-03-02T06:00:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58550"},"wordCount":426,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58550#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0207.webp","keywords":["Cancer","HKG: 9969","InnoCare Pharma","Pediatric drugs","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58550#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58550","url":"https:\/\/flcube.com\/?p=58550","name":"InnoCare's Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58550#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58550#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0207.webp","datePublished":"2026-03-02T06:00:50+00:00","dateModified":"2026-03-02T06:00:51+00:00","description":"InnoCare Pharma Limited (SHA:\u202f688428, HKG:\u202f9969) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Priority Review to zurletrectinib (ICP\u2011723) orally disintegrating tablets for the treatment of pediatric patients (ages 2\u201312) with solid tumors harboring NTRK gene fusions. The designation follows the December\u202f2025 approval for adult and adolescent patients (\u2265\u202f12 years), expanding the next\u2011generation TRK inhibitor's addressable population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58550#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58550"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58550#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0207.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0207.webp","width":1080,"height":608,"caption":"InnoCare's Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58550#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare&#8217;s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors \u2013 Next\u2011Gen TRK Inhibitor Expands Label"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0207.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58550"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58550\/revisions"}],"predecessor-version":[{"id":58553,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58550\/revisions\/58553"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58552"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}